Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Alison Oliveto

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Oliveto, Alison

PropertyValue
overview Historically, my career aims have been to improve upon treatments/ treatment access for substance use disorder as well as generally facilitate research in addiction and beyond. As a trained behavioral pharmacologist, I have had continuous NIH funding since 1993 conducting translational research in addiction, including human laboratory and clinical trials, with a focus on psychostimulant and/or opioid use disorders. In 1996 during my tenure at Yale School of Medicine, I established and directed the Outpatient Treatment Research Program at the West Haven CT Veterans Administration Healthcare System (VAHCS) that administratively involved three institutions (Yale, VAHCS, APT Foundation) to ensure the successful conduct of several medications development human laboratory and clinical trials. In 1998 I became Scientific Director of the NIDA P50 medications development center (T. Kosten, PI) and was responsible for coordinating the mentoring of physician scientists and fellows, overseeing research staff, and consolidating resources to maximize research productivity. When I accepted a faculty position at UAMS in 2004, I moved my research and established an addiction research program in the department of Psychiatry and became Vice Chair for Research in Psychiatry at UAMS. I have been responsible for intramural and extramural grant funding, overseeing the career development of clinician scientists, and establishing a research track for Psychiatry residents. I served in several leadership roles on campus, including in our CTSA-funded Translational Research Institute from 2014-2017. I directed the UAMS CTSA-supported Clinical Trials Unit, transforming culture and processes to maximize efficient, regulatory-compliant and rigorous conduct of multi-site trials. I became Director of Psychiatry's Center for Addiction Research in 2016 and have focused on strategic recruitment of addiction scientists as well as developing synergy among CAR/UAMS faculty. In 2020, I became the UAMS site principal investigator in the NIDA Clinical Trials Network Big/SouthWest Node and am awaiting funding on a NIDA CTN multi-site trial. Meanwhile, my focus has shifted to include drug prevention strategies and am currently leading the Arkansas State Epidemiological Outcomes Workgroup in partnership with state agencies, gathering, analyzing and disseminating trends in substance abuse and related outcomes in order to inform prevention efforts across the state.
research overview A behavioral pharmacologist by training, I have been a funded NIH researcher for over four decades, conducting translational research focused mainly on opioid and/or stimulant use disorders. Much of my work has focused on developing human laboratory and clinical trial study designs that serve as models for studying efficacious treatments. For instance, I participated in the development and testing of a methodological advance in human drug discrimination procedures (novel-response option) and applied this methodological advance to a human laboratory model of opioid withdrawal, through which two nonopioid compounds were identified as potential opioid withdrawal treatments. Moreover, my Yale colleague, Dr. Patrick O’Connor, and I piloted the first trial of office-based buprenorphine treatment for opioid use disorder. In addition, I developed in collaboration with Dr. Thomas Kosten a relapse paradigm for stimulant use disorder trials and identified the SSRI sertraline as a potentially efficacious relapse prevention treatment. I also mentored Dr. Michael Mancino (UAMS) on the development of a rigorous amphetamine withdrawal paradigm for his COBRE project (PI: Garcia-Rill) and Dr. Michael Wilson (UAMS) on developing a human laboratory model of “agitation”, which often occurs among methamphetamine users presenting to the ED. I am currently leading the Arkansas Statewide Epidemiology Outcomes Workgroup, monitoring substance use trends and related outcomes to help guide successful substance use prevention efforts in the state. Along these lines, I have been working with Dr. Ronald Thompson (UAMS) on developing and testing the efficacy of an adolescent game-based nonmusical prescription drug use prevention intervention along with a caregiver educational component. Meanwhile, I have returned to my behavioral pharmacology roots, piloting the effects of cannabis in older adults.

One or more keywords matched the following items that are connected to Oliveto, Alison

Item TypeName
Academic Article Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients.
Academic Article Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients.
Academic Article Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management.
Academic Article Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study.
Academic Article Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study.
Academic Article Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Academic Article Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients.
Academic Article Effects of disulfiram on QTc interval in non-opioid-dependent and methadone-treated cocaine-dependent patients.
Academic Article Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients.
Academic Article Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response.
Academic Article Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients.
Academic Article Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers.
Academic Article Treatment of heroin (diamorphine) addiction: current approaches and future prospects.
Concept Treatment Outcome
Concept Substance Abuse Treatment Centers
Concept Opiate Substitution Treatment
Academic Article Gender differences in response to disulfiram treatment for cocaine dependence in methadone-stabilized opioid- and cocaine-dependent individuals
Academic Article New Treatments for Opiate Dependence
Academic Article Depression predicts poor treatment response with desipramine and methadone or buprenorphine among cocaine and opioid dependent patients
Academic Article Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials.
Grant Center for Translational Neuroscience
Grant Improving Treatment Strategies for Prescription Opioid Use Disorder- Resubmission
Grant Improving Treatment Outcomes for Prescription Opioid Dependence - Continuation - Continuation - Continuation - Continuation
Grant Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
Academic Article Survey of Treatment Preferences for Opioid Use Disorder.
Academic Article Intramuscular medication for treatment of agitation in the emergency department: A systematic review of controlled trials.
Grant Improving Treatment Outcomes for Prescription Opioid Dependence
Grant The impact of buprenorphine on sleep, mood and cognition in opioid use disorder patients participating in a medication assisted treatment program
Grant Expanding Access to Medication Assisted Treatment Across the State of Arkansas
Grant Medication Assisted Treatment for Opioid Use Disorders among Rural and Uninsured or Underinsured Arkansans
Academic Article Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program.
Academic Article Characteristics of patients undergoing medication-assisted -treatment for opioid use disorder and their interest in Tai Chi practice.
Grant Randomized, CSP-1036: Randomized, Placebo-Controlled, Multi-Site Trial of Extended-Release Naltrexone Injection/Bupropion XL Tablets in the Treatment of Methamphetamine Use Disorder (MURB)
Grant Improving Combined Buprenorphine-Behavioral Treatment
Academic Article A randomized clinical trial of disulfiram at higher doses for the treatment of cocaine use disorder among methadone-stabilized patients.

Search Criteria
  • Therapeutics